Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 796 to 810 of 1688 results for carers

  1. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

    In development [GID-TA11430] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors (CG110)

    This guideline covers antenatal care for all pregnant women with complex social factors (particularly alcohol or drug misuse, recent migrant or asylum seeker status, difficulty reading or speaking English, aged under 20, domestic abuse). It offers advice on improving access to care, maintaining contact with antenatal carers, and additional information and support for these women.

    Clinical guideline
    Published
    22 September 2010
    View recommendations

    Sections for CG110

  3. Dementia. Patient decision aid on enteral (tube) feeding for people living with severe dementia

    assessment, management and support for people living with dementia and their carers c NICE 2018. All rights reserved. Subject to Notice...

  4. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development [GID-TA11219] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development [GID-TA11303] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

    Diagnostics guidance
    Last updated
    19 December 2017
    View recommendations

    Sections for DG14

  9. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  10. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. OrganOx metra for liver transplant [ID5116]

    In development [GID-TA11035] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development [GID-TA11216] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development [GID-TA11484] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  15. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development